Thyroid Cancer: Types, Radioactive Iodine Therapy, and Thyroidectomy Explained
Mar, 6 2026
Thyroid cancer is one of the fastest-growing cancer diagnoses in the U.S., with over 44,000 new cases each year. Yet despite the rising numbers, most people diagnosed with it have an excellent chance of long-term survival. The reason? Modern treatment works remarkably well-when it’s used correctly. Many patients undergo more treatment than they need, while others with higher-risk disease don’t get enough. Understanding the types of thyroid cancer, how radioactive iodine therapy works, and what thyroidectomy really means can help you make smarter decisions-if you’re facing this diagnosis or supporting someone who is.
What Are the Main Types of Thyroid Cancer?
The thyroid gland has four main cancer types, each with different behaviors and treatment needs. Papillary thyroid carcinoma is the most common type, making up 70% to 80% of all cases. It grows slowly, often stays confined to the thyroid, and spreads to lymph nodes in the neck but rarely to distant organs. Even when it does spread, it usually responds well to treatment. Most patients under 45 have a 10-year survival rate above 98%.
Follicular thyroid carcinoma accounts for 10% to 15% of cases. It tends to spread through the bloodstream to the lungs or bones rather than lymph nodes. It’s harder to detect early because it doesn’t always show up on ultrasound. But like papillary cancer, it absorbs iodine, which makes radioactive iodine therapy effective.
Medullary thyroid carcinoma is rare, at 3% to 5%. It comes from a different cell type in the thyroid and doesn’t take up iodine. That means radioactive iodine won’t work. Many cases are linked to inherited gene mutations, especially in the RET gene. Blood tests for calcitonin and genetic screening are critical for families with a history.
Anaplastic thyroid carcinoma is the rarest and deadliest, under 2% of cases. It grows so fast that symptoms appear suddenly-neck swelling, trouble swallowing, hoarseness. By the time it’s found, it’s often spread beyond the thyroid. Survival is measured in months, not years. Treatment requires surgery, radiation, and targeted drugs, but outcomes remain poor.
How Radioactive Iodine Therapy Works (and When It Doesn’t)
Radioactive iodine therapy, or RAI, uses a form of iodine called I-131. The thyroid is the only part of the body that absorbs iodine, so when you swallow a capsule or liquid containing I-131, it travels straight to thyroid tissue-cancerous or not-and destroys it with radiation. This treatment has been used since the 1940s and remains the gold standard for differentiated thyroid cancers (papillary and follicular).
RAI serves two main purposes: ablation and treatment. Ablation means wiping out leftover thyroid tissue after surgery so doctors can monitor for cancer recurrence using blood tests. Treatment means targeting known cancer that has spread to lymph nodes or distant organs like the lungs.
Doses vary. For ablation, 30 mCi may be enough-especially for low-risk patients. For metastatic disease, doses can go as high as 200 mCi. The HiLo trial showed no difference in outcomes between 30 mCi and 100 mCi for low-risk patients. That’s led many centers to reduce doses, cutting radiation exposure by 70% without hurting results.
But RAI doesn’t work for everyone. Medullary and anaplastic cancers don’t absorb iodine because they lose the sodium-iodide symporter protein. For these, radiation therapy, surgery, or targeted drugs like selpercatinib (for RET mutations) or dabrafenib/trametinib (for BRAF mutations) are used instead. Even in papillary cancer, if the tumor stops taking up iodine after one or two treatments, RAI becomes useless. That’s called RAI-refractory disease-and it’s a major challenge.
Thyroidectomy: What Surgery Really Means
Most thyroid cancer patients will have surgery. But not all surgeries are the same. The two main types are lobectomy and total thyroidectomy.
Lobectomy removes one lobe of the thyroid. It’s often enough for small papillary cancers under 1 cm that haven’t spread. Recovery is quick-most people go home the same day. But if cancer is found later to be more aggressive, a second surgery (called a completion thyroidectomy) may be needed.
Total thyroidectomy removes the entire gland. This is standard for larger tumors, cancers that spread to lymph nodes, or when RAI is planned. The incision is 6 to 8 cm, and patients usually stay one or two nights. The surgery takes 2 to 3 hours. Surgeons now routinely use nerve monitors to protect the recurrent laryngeal nerves-those that control the voice. Still, about 1 in 20 patients have temporary voice changes, and 1 in 10 have permanent hypoparathyroidism, which means their parathyroid glands (tiny glands behind the thyroid) get damaged and can’t regulate calcium.
Some newer techniques, like robotic or transoral (scarless) surgery, promise no neck scar. But studies show complication rates are higher-12.4% versus 8.9% for traditional open surgery. Most experts still recommend open surgery for safety and precision.
After total thyroidectomy, you’ll need lifelong thyroid hormone replacement (levothyroxine). The dose isn’t just to replace hormones-it’s also to suppress TSH (thyroid-stimulating hormone), because TSH can fuel cancer growth. For intermediate-risk patients, doctors aim for TSH between 0.5 and 2.0 mIU/L.
Preparation for Radioactive Iodine Therapy
Before RAI, your body needs to be in a state that makes the thyroid cells hungry for iodine. There are two ways to do this: thyroid hormone withdrawal or recombinant human TSH (Thyrogen®).
Thyroid hormone withdrawal means stopping your levothyroxine for 2 to 4 weeks. This causes hypothyroidism-fatigue, weight gain, brain fog, muscle cramps. Many patients say this is harder than the surgery. Some even describe it as feeling like a severe flu.
Thyrogen® is an injection that raises TSH without stopping hormone replacement. It’s more expensive and not covered by all insurers, but it avoids the misery of withdrawal. It’s now the preferred method for most patients who qualify.
Either way, you’ll need to follow a low-iodine diet for 1 to 2 weeks before treatment. That means no salt (unless labeled iodine-free), no dairy, eggs, seafood, soy, or baked goods with additives. It’s strict-and many patients find it overwhelming.
What Happens After Treatment?
Recovery after surgery and RAI isn’t just about healing. It’s about managing side effects and long-term monitoring.
After total thyroidectomy, calcium levels must be watched closely. Low calcium causes tingling, muscle spasms, and even seizures. Many patients need calcium and vitamin D supplements for months-or permanently.
RAI patients are isolated for a few days because they emit radiation. They can’t be near children or pregnant people. They must flush the toilet twice after using it and wash their dishes separately. These rules are strict but necessary.
Follow-up includes blood tests for thyroglobulin (a protein made by thyroid cells) and TSH, plus neck ultrasounds. If thyroglobulin rises, it signals cancer recurrence. Some patients have scans every 6 months for life.
Quality of life matters. A 2023 survey of over 1,200 survivors found 68% still had symptoms like fatigue and brain fog despite taking thyroid hormone. Only 32% felt fully recovered. Voice changes, dry mouth from RAI, and anxiety about recurrence are common.
When Is Less Treatment Better?
One of the biggest shifts in thyroid cancer care is recognizing that not every small cancer needs surgery or RAI. For papillary microcarcinomas under 1 cm-with no lymph node spread, no aggressive features, and no family history-active surveillance is now an option.
Studies from Japan show only 3.8% of these tiny tumors grow or spread over 10 years. Many U.S. doctors now recommend monitoring with yearly ultrasounds instead of rushing to operate. Up to 30% of patients are overtreated with unnecessary total thyroidectomies or RAI, according to experts at Memorial Sloan Kettering.
But this only works for low-risk cases. If your cancer is larger than 1 cm, has spread to lymph nodes, or has aggressive features like vascular invasion, then surgery and possibly RAI are still the right path.
What’s Next for Thyroid Cancer Treatment?
The field is moving fast. In 2023, the AJCC staging system updated to include molecular markers like BRAF and TERT mutations to better predict risk. New drugs like selpercatinib and dabrafenib/trametinib are changing outcomes for medullary and anaplastic cancers.
Researchers are testing drugs that can make RAI-refractory cancers “redifferentiate”-meaning they start absorbing iodine again. In phase II trials, selumetinib restored RAI uptake in 54% of patients. That could bring back a life-saving treatment for those who lost it.
Liquid biopsies-blood tests that detect tumor DNA-are being studied to replace frequent scans. And immunotherapy is being tested in aggressive cases, though results so far are mixed.
One major gap: access. Rural patients have 28% higher death rates than urban ones, likely because they can’t reach specialized thyroid cancer centers. The American Thyroid Association’s 2025 plan aims to fix that.
Thyroid cancer isn’t one disease. It’s a spectrum-from tiny, harmless nodules to deadly tumors that demand everything we have. The key is matching the treatment to the cancer, not the fear. That’s where real progress is happening.
Is thyroid cancer always deadly?
No. Most thyroid cancers-especially papillary and follicular types-are highly treatable. The 10-year survival rate for papillary cancer in patients under 45 is over 98%. Even in cases with spread to lymph nodes, survival remains very high. Only anaplastic thyroid cancer has a poor prognosis, with a 5-year survival rate below 10%.
Do I need radioactive iodine after thyroid surgery?
Not always. For small, low-risk papillary cancers (under 1 cm) without spread, RAI is often unnecessary. Guidelines now recommend it only if the tumor is larger than 1 cm, has spread to lymph nodes, or shows aggressive features. For medullary or anaplastic cancers, RAI doesn’t work at all. Your doctor will use tumor size, stage, and molecular markers to decide.
What are the risks of thyroidectomy?
The main risks are damage to the recurrent laryngeal nerves (which can cause hoarseness or voice loss) and injury to the parathyroid glands (which can lead to low calcium levels). Temporary voice changes happen in about 10% of cases; permanent changes occur in 1-2%. Permanent hypoparathyroidism requiring calcium supplements affects about 1 in 10 patients. Nerve monitoring during surgery reduces these risks significantly.
How long does it take to recover from thyroid surgery?
Recovery varies. After a lobectomy, most people return to normal activities in 3-5 days. After a total thyroidectomy, expect 2-4 weeks of recovery. Driving is restricted for 7-10 days, and heavy lifting is limited for 3 weeks. Hormone replacement starts immediately, but it may take weeks to find the right dose. RAI preparation and recovery add another 2-4 weeks.
Can thyroid cancer come back after treatment?
Yes, but recurrence is often treatable. Papillary and follicular cancers can return years later, usually in the neck lymph nodes. Recurrence is detected through rising thyroglobulin levels or ultrasound. Most recurrences are caught early and treated successfully with surgery or RAI. Long-term monitoring with blood tests and scans is essential for life.
Sean Callahan
March 6, 2026 AT 15:07Adebayo Muhammad
March 7, 2026 AT 09:47Pranay Roy
March 9, 2026 AT 01:39Joe Prism
March 10, 2026 AT 18:56Bridget Verwey
March 11, 2026 AT 14:07Andrew Poulin
March 13, 2026 AT 07:29Vikas Verma
March 14, 2026 AT 06:50Susan Purney Mark
March 14, 2026 AT 20:14Ian Kiplagat
March 15, 2026 AT 01:34Amina Aminkhuslen
March 16, 2026 AT 17:25amber carrillo
March 18, 2026 AT 09:48Tim Hnatko
March 19, 2026 AT 23:34